Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's ...

In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inozyme Pharma (INZY – Research Report) and ...

The three companies are the most likely to be acquired in Needham's coverage universe, Needham analyst Joseph Stringer wrote in a note on Friday. Needham has a buy rating and $26 price target on ...

Also Read: MDJM Debuts Its E-Commerce Platform: Details Needham analyst Joseph Stringer writes that the IPF program was the main value driver for Pliant Therapeutics. The remainder of the pipeline ...